Sanofi drives digital transformation with Google Cloud

THOMAS KURIAN | June 18, 2019 | 177 views

My conversations with healthcare customers have made it clear that the industry is moving to a more data-centric model, one that can deliver deeper insights to physicians, help them make better-informed decisions, and provide better care for patients. This transformation goes hand in hand with Google's mission to organize the world’s information and make it universally accessible, secure and useful.

Spotlight

Medicus International

Medicus International brings to our clients expertise across all areas of strategic consultancy, including market analysis, competitor intelligence.

OTHER ARTICLES
BUSINESS INSIGHTS

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | June 30, 2022

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More
PHARMA TECH

What are the advantages of PCD Pharma Company?

Article | October 6, 2022

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More
PHARMA TECH

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | July 20, 2022

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Spotlight

Medicus International

Medicus International brings to our clients expertise across all areas of strategic consultancy, including market analysis, competitor intelligence.

Related News

Sanofi to leverage Aetion’s data analytics platform to get real world evidence of drug efficacy

MedCity News | November 21, 2019

French drugmaker Sanofi announced Wednesday that it is leveraging the data analytics platform of New York-based Aetion to gather real-world evidence that can advance its understanding of the effectiveness, safety, and value of drugs. Specifically, Aetion’s platform will be integrated with Sanofi’s real-world data platform called Darwin. Per the announcement of this collaboration and company-wide integration, Sanofi’s DARWIN compiles and analyzes de-identified data from hundreds of millions of patients who are battling various diseases. Meanwhile, Aetion’s platform analyzes real-world data to answer questions about which drugs are effective, safe and can actually improve outcomes. “Today marks another important step in Sanofi’s digital transformation,” said Bernard Hamelin, Global Head of Medical Evidence Generation, Sanofi, in a news release. “By integrating these platforms we strive to make faster, more informed decisions that will lead to first-in-class and best-in-class treatments that can change the practice of medicine.” In the same announcement, Aetion’s CEO hailed the collaboration as a strong indication of the potential of real-world evidence in the future.

Read More

Sanofi opens digital manufacturing facility in the US

Pharmaceutical Technology | October 15, 2019

French pharmaceutical giant Sanofi has opened a digital manufacturing facility at Framingham in Massachusetts, the US for continuous production of biologics. The facility will use intensified technology to link the production process with research and development. The company expects the approach to improve the commercialisation of drugs. Sanofi notes that the facility will boost its strategy to focus on biologics, supporting the transformation of its R&D pipeline. Sanofi global industrial affairs executive vice-president Philippe Luscan said: “Our Framingham facility leads the way in delivering the next generation of biologics manufacturing, leveraging intensified, continuous processing in a fully integrated digitally powered facility. “This opening demonstrates we are at the leading edge of innovation and manufacturing excellence, helping us to shape the future of both our company and the industry.”

Read More

FDA set to review Sanofi’s isatuximab for multiple myeloma

Pharmatimes | July 11, 2019

The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for isatuximab for a review, for the indication of relapsed/refractory multiple myeloma (RRMM). The drug’s maker Sanofi has announced that the target action date for the FDA decision is April 30, 2020. The drug is an investigational monoclonal antibody that targets a specific epitope on the CD38 receptor of a plasma cell and its BLA is based on positive results from ICARIA-MM, an open-label pivotal Phase III clinical trial of isatuximab in patients with RRMM. During the trial, isatuximab was administered through an intravenous infusion at a dose of 10mg/kg once weekly for four weeks, then every other week for 28-day cycles in combination with standard doses of pomalidomide and dexamethasone for the duration of treatment, and was found to prolong progression-free survival by five months versus Pomalyst and dexamethasone alone in patients. “We are excited by these results, which represent significant progress in our ambition to extend the lives of multiple myeloma patients,” said John Reed, head of Research and Development at Sanofi. “We look forward to engaging with regulatory authorities with the goal of bringing this potential new treatment to patients as quickly as possible.” The drug is currently being evaluated in multiple ongoing Phase III clinical trials in combination with current standard treatments for people with relapsed/refractory or newly diagnosed multiple myeloma, as well as being under investigation for the treatment of other hematologic malignancies and solid tumours.

Read More

Sanofi to leverage Aetion’s data analytics platform to get real world evidence of drug efficacy

MedCity News | November 21, 2019

French drugmaker Sanofi announced Wednesday that it is leveraging the data analytics platform of New York-based Aetion to gather real-world evidence that can advance its understanding of the effectiveness, safety, and value of drugs. Specifically, Aetion’s platform will be integrated with Sanofi’s real-world data platform called Darwin. Per the announcement of this collaboration and company-wide integration, Sanofi’s DARWIN compiles and analyzes de-identified data from hundreds of millions of patients who are battling various diseases. Meanwhile, Aetion’s platform analyzes real-world data to answer questions about which drugs are effective, safe and can actually improve outcomes. “Today marks another important step in Sanofi’s digital transformation,” said Bernard Hamelin, Global Head of Medical Evidence Generation, Sanofi, in a news release. “By integrating these platforms we strive to make faster, more informed decisions that will lead to first-in-class and best-in-class treatments that can change the practice of medicine.” In the same announcement, Aetion’s CEO hailed the collaboration as a strong indication of the potential of real-world evidence in the future.

Read More

Sanofi opens digital manufacturing facility in the US

Pharmaceutical Technology | October 15, 2019

French pharmaceutical giant Sanofi has opened a digital manufacturing facility at Framingham in Massachusetts, the US for continuous production of biologics. The facility will use intensified technology to link the production process with research and development. The company expects the approach to improve the commercialisation of drugs. Sanofi notes that the facility will boost its strategy to focus on biologics, supporting the transformation of its R&D pipeline. Sanofi global industrial affairs executive vice-president Philippe Luscan said: “Our Framingham facility leads the way in delivering the next generation of biologics manufacturing, leveraging intensified, continuous processing in a fully integrated digitally powered facility. “This opening demonstrates we are at the leading edge of innovation and manufacturing excellence, helping us to shape the future of both our company and the industry.”

Read More

FDA set to review Sanofi’s isatuximab for multiple myeloma

Pharmatimes | July 11, 2019

The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for isatuximab for a review, for the indication of relapsed/refractory multiple myeloma (RRMM). The drug’s maker Sanofi has announced that the target action date for the FDA decision is April 30, 2020. The drug is an investigational monoclonal antibody that targets a specific epitope on the CD38 receptor of a plasma cell and its BLA is based on positive results from ICARIA-MM, an open-label pivotal Phase III clinical trial of isatuximab in patients with RRMM. During the trial, isatuximab was administered through an intravenous infusion at a dose of 10mg/kg once weekly for four weeks, then every other week for 28-day cycles in combination with standard doses of pomalidomide and dexamethasone for the duration of treatment, and was found to prolong progression-free survival by five months versus Pomalyst and dexamethasone alone in patients. “We are excited by these results, which represent significant progress in our ambition to extend the lives of multiple myeloma patients,” said John Reed, head of Research and Development at Sanofi. “We look forward to engaging with regulatory authorities with the goal of bringing this potential new treatment to patients as quickly as possible.” The drug is currently being evaluated in multiple ongoing Phase III clinical trials in combination with current standard treatments for people with relapsed/refractory or newly diagnosed multiple myeloma, as well as being under investigation for the treatment of other hematologic malignancies and solid tumours.

Read More

Events